Novocure Promotes President Frank Leonard to CEO

Novocure has appointed Frank Leonard as its new chief executive officer (CEO), effective immediately.

Leonard was previously president of Novocure and succeeds Ashley Cordova, who has resigned from the company. Novocure’s executive chairman said that during his over 15-year career at the company, Leonard headed many global business operations and developed deep expertise in delivering the company’s unique, cancer-based device therapy.

“Frank has been instrumental in creating Novocure’s culture and guiding the organization at critical points, including preparing the company for its first commercial launch and establishing the business functions that continue to drive our growth,” Doyle told the press. “Frank embodies Novocure’s core values and has an unwavering commitment to our patient-forward mission. He is the ideal person to lead our organization through the exciting, transformative milestones anticipated in the years ahead. We are thrilled for him to step into the CEO role.”

“On behalf of the Novocure Board of Directors, I want to thank Ashley Cordova for the contributions she made to our organization during her career at Novocure. She was unquestionably dedicated to our mission and helped build Novocure into the company it is today. We wish her success in her future endeavors,” continued Doyle.

The global oncology company is working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its Tumor Treating Fields therapy. Novocure’s products are approved in certain countries to treat adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma, and pleural mesothelioma.

Leonard was appointed president in June 2025 after leading the company’s global business operations since January 2024. He began leading Novocure’s U.S. business in October 2022, after serving as chief development officer from September 2020 to September 2022. Leonard joined the company in 2010 to prepare for its first commercial launch and had leadership roles in Novocure’s finance, reimbursement, and business development segments. He’s also led the company’s early innovation and product development teams.

As Novocure’s president, he led global sales, marketing, field medical affairs, patient experience, public affairs, market access, and product and portfolio strategy functions.

“The patient is at the center of what we do and why we are committed to extending survival in the most aggressive cancers,” Leonard said. “I am honored to lead Novocure and partner with our incredible employees around the world as we prepare to launch products in new indications, complete multiple clinical trials, and work to deliver the full potential of our innovative therapy.”